HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone) (HAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01023620|
Recruitment Status : Completed
First Posted : December 2, 2009
Results First Posted : October 8, 2019
Last Update Posted : October 8, 2019
This study is being done to better understand why people with HIV who have taken drugs for HIV begin to show abnormal changes in fat loss or fat gain in their bodies. This condition is called lipodystrophy.
Patients who take medicine for HIV and who have lipodystrophy report loss of subcutaneous (sc) fat from the arms, legs, and face and excess fat gain in the neck and truncal region. They also more likely to have problems with insulin in the body, high fat levels in the blood and diabetes. The reason that lipodystrophy develops is not fully understood although some HIV drugs have are very likely the cause. The complications pose an increased risk of fat blockage forming in the arteries making you more at risk for heart problems in the future. Changes in body fat can cause physical discomfort and psychological distress. Management of these problems can be a challenge for the patient's doctor.
The investigators propose data collection to determine if there is more than one reason why this might happen in some people and not in others. Laboratory samples being collected: 1) special imaging of the liver; 2) fat collected by needle from the mid thigh and mid-shoulder areas; 3) blood samples to measure the virus, t-cells, fats, and other markers of how the patient's body is handling the virus.
This study is being done because science does not fully understand why some patients with HIV who take medicines for the virus have abnormal fat loss or gain and some do not. This research study is intended to help us better understand why and how this happens.
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections||Drug: Pioglitazone Other: Observation||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||4 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Human Immunodeficiency Virus Acquired Lipodystrophy (HAL) Classification, Measurement, & Fat Response to a Thiazolidinedione (TZD) Challenge in Differing Adult Phenotypic Presentations|
|Actual Study Start Date :||October 2009|
|Actual Primary Completion Date :||May 31, 2010|
|Actual Study Completion Date :||May 31, 2010|
10 male patients with lipodystrophy taking daily Pioglitazone 45 mg
Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
Other Name: Actos
Sham Comparator: Observation/Comparison
10 male patients with lipodystrophy not taking daily Pioglitazone
Participants will be observed for 16 weeks but will not receive drug
Other Name: Comparison
- Percent of Liver Fat Pre/Post Challenge With Daily Pioglitazone 45 mg [ Time Frame: 16 weeks ]No data are available for this study as the PI has left the institution. Multiple efforts to contact the PI for the relevant data have failed
- Fine Needle Aspiration of Fat Pre/Post With Daily Pioglitazone 45 mg [ Time Frame: 16 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01023620
|United States, Texas|
|UT Southwestern Medical Center at Dallas|
|Dallas, Texas, United States, 75390-9173|
|Principal Investigator:||Nancy Rollins, MD||UT Southwestern Medical Center at Dallas|